ERBB2 and inflammatory breast carcinoma: A subgroup analysis of 62 patients with HER2+ IBC enrolled in a large phase 3 trial (NOAH trial) reported a 54.8% in breast pCR to neoadjuvant trastuzumab in combination with chemotherapy, versus 19.3% for patients receiving only chemotherapy (p = 0.004) [43].